Cellectar Biosciences, Inc. Resources

Patients News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Platform
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • Iopofosine
  • Clinical Studies
    • Overview
    • Waldenstrom’s Macroglobulinemia Pivotal Study Recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Study Recruiting
    • Children With Relapsed or Refractory Malignant Cancer Clinical Study Recruiting
  • Patients
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update

Nov 8, 2021

Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer

Nov 2, 2021

Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies

Oct 25, 2021

Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer

Sep 22, 2021

Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Sep 15, 2021

Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia

Aug 18, 2021

Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131

Aug 16, 2021

Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update

Aug 9, 2021

Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.

Jul 13, 2021

Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs)

Jul 12, 2021
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...30
    © 2023 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A